Hi James, Just a quick question regarding Cantrixil. I read that Final Data from P1 study was due at ESMO 19-21 September 2020 (Hidden Gems Webinar). Also I noticed that Cantrixil was left out of P16 on the HC Wainwright presentation. Any possible update on this would be appreciated. Thank you for all the work you & the team have been doing & I like many others look forward to the data read outs over the next 6-12 months regarding both Paxalisib & Cantrixil. Regards, MrDB
Dear MrDB, After discussion with the investigators, we decided not to put Cantrixil into the ESMO conference. Like many conferences, this has moved to a wholly virtual format, and we took the view that it would not provide good exposure for the final data from the study. We are working to find a better forum to present the definitive results. Meanwhile, as reflected in our more recent guidance, we expect to share at least top-level data in the second half. All best wishes, James.
”we expect to share at least top-level data in the second half”
the company has always indicated that they would do a deal / partnership regarding Cantrixil
- Forums
- ASX - By Stock
- KZA
- Cantrixil
Cantrixil
-
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)